GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2010

Pfizer Pays $240M for 40% Stake in Teuto to Boost Presence in Brazilian Generics Market

Pfizer Pays $240M for 40% Stake in Teuto to Boost Presence in Brazilian Generics Market

Pact covers drug-development deals and potential for acquisition of remaining stake in 2014.[Dana Britton - Fotolia.com]

  • Pfizer is buying 40% of Brazilian generics firm Teuto Brasileiro for about $240 million up front plus performance-based milestones. The U.S. drugs giant also retains an option to acquire the remaining 60% of Teuto in 2014, while the latter’s shareholders have an option to sell their 60% stake to Pfizer beginning in 2015. The two companies are in addition embarking on a series of agreements to develop and commercialize generic medicines.

    Teuto has a portfolio of about 250 products in over 400 presentations. Pfizer claims having a stake in the firm will boost its position in Brazil as a key emerging market. The deal will give Pfizer access to significant distribution networks in the country along with and the opportunity to register and commercialize a range of Teuto’s products in markets outside Brazil under its own brands. Teuto will separately have access to certain Pfizer products for distribution and marketing in Brazil under the Teuto brand.

    “We believe this partnership will enable both companies to effectively build upon one another’s core capabilities and areas of expertise,” comments Jean-Michel Halfon, president of Pfizer’s emerging markets business. “This agreement demonstrates Pfizer’s commitment to pursue focused investments in key emerging markets to accelerate our growth and increase patient access to high-quality medicines.”

    Pfizer maintains branded and unbranded generics now accounts for approximately 60% of the Brazilian retail pharmaceuticals market, driven by the increasing purchasing power of middle and lower-middle income patients.


Readers' Comments

Posted 10/23/2010 by Dahlia Lee

Vitamin B12 might actually decrease the likelihood of creating Alzheimer's disease, accounts BBC News Health. A research published recently in Neurology of 271 65- to 79-year-old Finnish individuals conducted over the course of seven years found that lower levels of vitamin B12 within the blood could possibly be connected to instances of senior dementia. I found this here: Vitamin B12 may help delay Alzheimer's disease, study says The ages of the analysis group correspond to ages of those at greatest risk for developing dementia. They did not have dementia at the beginning of the study. However the experts are not sold yet. Vitamin B12 might be the break science has been looking for against Alzheimer's ailment, however additional tests will be necessary to prove that conclusively.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?